Keros Therapeutics (KROS) Accumulated Expenses (2019 - 2025)
Historic Accumulated Expenses for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $15.2 million.
- Keros Therapeutics' Accumulated Expenses fell 3155.31% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 3155.31%. This contributed to the annual value of $20.9 million for FY2024, which is 1647.51% up from last year.
- Per Keros Therapeutics' latest filing, its Accumulated Expenses stood at $15.2 million for Q3 2025, which was down 3155.31% from $20.0 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Accumulated Expenses ranged from a high of $22.2 million in Q3 2024 and a low of $5.5 million during Q1 2021
- For the 5-year period, Keros Therapeutics' Accumulated Expenses averaged around $12.4 million, with its median value being $12.2 million (2023).
- In the last 5 years, Keros Therapeutics' Accumulated Expenses soared by 8770.55% in 2021 and then crashed by 3155.31% in 2025.
- Over the past 5 years, Keros Therapeutics' Accumulated Expenses (Quarter) stood at $7.3 million in 2021, then soared by 73.77% to $12.8 million in 2022, then soared by 40.5% to $17.9 million in 2023, then grew by 16.48% to $20.9 million in 2024, then fell by 27.29% to $15.2 million in 2025.
- Its Accumulated Expenses stands at $15.2 million for Q3 2025, versus $20.0 million for Q2 2025 and $17.3 million for Q1 2025.